1 / 6

Hyperhidrosis Therapeutics Pipeline to Witness Numerous Collaborations in Future

Hyperhidrosis Therapeutics Pipeline Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial, Preclinical Research & Discovery Stage Insights

NidhiNehani
Download Presentation

Hyperhidrosis Therapeutics Pipeline to Witness Numerous Collaborations in Future

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hyperhidrosis Therapeutics Pipeline to Witness Numerous Collaborations in Future

  2. Hyperhidrosis Therapeutics Hyperhidrosis therapeutics pipeline in 2017 The study analyzed that the hyperhidrosis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Access Report summary with Detailed TOC on "Hyperhidrosis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.psmarketresearch.com/market-analysis/hyperhidrosis-therapeutics-pipeline-analysis

  3. Hyperhidrosis Therapeutics Insights on pipeline segments Allergan Plc, TheraVida Inc., and GlaxoSmithKline Plc have one drug candidate each in the Phase II development for the treatment of hyperhidrosis. Glycopyrroniumtosylate is the only drug candidate that has the Phase III stage of development for the treatment of hyperhidrosis. Majority of the pipeline drug candidates are being developed using the topical route of administration.

  4. Hyperhidrosis Therapeutics Various collaborations for hyperhidrosis drug development In March 2015, Kaken Pharmaceutical Co., Ltd. and Brickell Biotech, Inc. entered in an agreement concerning the exclusive licensing and joint development of BBI-4000. Under the terms of agreement Brickell Biotech, Inc. agreed to conduct a Phase IIb clinical trial of BBI-4000 in the U.S. for patients with primary focal hyperhidrosis.. Some of the key players developing drugs for the treatment of hyperhidrosis include Dermira, Inc., Allergan plc, TheraVida Inc. and others.

  5. Hyperhidrosis Therapeutics Download report sample at: https://www.psmarketresearch.com/market-analysis/hyperhidrosis-therapeutics-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related